Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

49.21 +0.36 (+0.74%)
Official Closing Price Updated: 5:00 PM EST, Nov 25, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,772,043
Open 48.93
Bid (Size) 49.15 (2)
Ask (Size) 49.29 (7)
Prev. Close 48.85
Today's Range 48.84 - 49.22
52wk Range 41.45 - 61.71
Shares Outstanding 5,606,688,356
Dividend Yield 3.17%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Is Novavax Stock a Buy Now?
There's probably not much good news coming for this biotech in the near future. 
Via The Motley Fool
Better Dividend Stock: AbbVie or Viatris?
These pharmaceutical companies are profitable and offer above-average dividends. 
Via The Motley Fool

Performance

YTD
-13.13%
-13.13%
1 Month
+7.59%
+7.59%
3 Month
+6.45%
+6.45%
6 Month
-7.22%
-7.22%
1 Year
-8.87%
-8.87%

More News

Read More
Nutraceutical Supplements Market to Witness Huge Growth : Glanbia, Pfizer, Bayer, DowDuPont
Via SBWire
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
8 Analysts Have This to Say About Pfizer
Via Benzinga
Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains
Via Benzinga
Is Now the Time for Income Investors to Buy This Big Pharma Stock?
Via The Motley Fool
Novavax Stock: Buy, Sell, or Hold in 2023?
Via The Motley Fool
Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle
Via Investor's Business Daily
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Via Benzinga
PFE Stock Could Be the Booster Shot Your Portfolio Needs Now
Via InvestorPlace
Graphic design as a service Company Doozoo secures strategic investment partner, launches fresh branding and expands resource within USA to meet growing global demand.
Via Get News
Jim Cramer Says China's Vaccines 'Don't Work' But Xi Won't Admit It
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Arvinas's ARV-471 Achieves Clinical Benefit Rate Of 38% In Breast Cancer Setting
Via Benzinga
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
From Arvinas Inc.
Via Globe NewsWire
2 Reasons to Buy Pfizer and 1 Reason to Sell
Via The Motley Fool
3 Unstoppable Growth Stocks to Buy and Hold
Via The Motley Fool
Here's What Value Stocks Can Do for a Growth Investor
Via The Motley Fool
Pfizer Is Worst-Performing US Large-Cap Pharma Stock This Year, Its Investment Case Is Complex Yet Rewarding
Via Benzinga
Pfizer/BioNTech's Omicron Tailored COVID-19 Vaccine Shows Improved Immune Response Against Emerging Omicron Sublineages
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Via Benzinga
Market Rally Holds Key Levels, But Breakouts Struggle; Walmart, Target, Nvidia In Focus: Weekly Review
Via Investor's Business Daily
Pfizer, BioNTech Take Next Step Toward A Pan-Covid Vaccine — But Is The Demand There?
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.